Dendreon (DNDN +4.4%) jumps after the CHMP renders a positive opinion on Provenge for the...

Dendreon (DNDN +4.4%) jumps after the CHMP renders a positive opinion on Provenge for the "treatment of asymptomatic or minimally symptomatic metastatic (non-visceral) castrate resistant prostate cancer." It will be interesting to watch how analysts react given the drug's Q1 numbers.

From other sites
Comments (3)
  • wired4acure
    , contributor
    Comments (46) | Send Message
    Pre-market reports (now pulled on TDameritrade) could not resist the temptation to slam DNDN even on this news-


    the ball is in play guys


    bigpharma really threatened now- European treatments are light years ahead - broader use of Provenge and a European partner loom large
    28 Jun 2013, 10:38 AM Reply Like
  • Bill Maurer
    , contributor
    Comments (7058) | Send Message
    Still months away from the final decision = closer to the ledge with a $100 million revenue quarter unlikely in the short term.
    28 Jun 2013, 10:42 AM Reply Like
  • XTigerX
    , contributor
    Comments (311) | Send Message
    DNDN = CRY still.


    Exotic expensive products. The pool of users of their products aren't big enough to drive their revenues as high as you would think given the prices of their products. Oh well, nevermind.
    28 Jun 2013, 11:58 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs